Drug Profile
Ecromeximab - Life Science Pharmaceuticals
Alternative Names: Anti-GD3 monoclonal antibody - Life Science Pharmaceuticals; KM-871; KW-2871Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Developer Kyowa Kirin; Life Science Pharmaceuticals; Ludwig Institute for Cancer Research
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 01 Dec 2014 Discontinued - Phase-I/II for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (IV) (Life Science Pharmaceuticals 2014 pipeline)
- 01 Dec 2014 Discontinued - Phase-II for Malignant melanoma (Combination therapy, Metastatic disease) in USA (IV) (Life Science Pharmaceuticals 2014 pipeline)
- 29 Sep 2011 Phase-II development is ongoing in USA